Alnylam Pharmaceuticals, Inc. vs Moderna, Inc.
A head-to-head of Alnylam Pharmaceuticals, Inc. (ALNY) and Moderna, Inc. (MRNA) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | ALNY | MRNA |
|---|---|---|
| Market Cap | $36.40B | $24.35B |
| P/E (TTM) | 74.51 | — |
| Forward P/E | 21.24 | -10.81 |
| P/S | 9.77 | 8.44 |
| P/B | 33.84 | 3.26 |
| EV/EBITDA | 44.53 | -6.46 |
| Dividend Yield | — | — |
| Profit Margin | 13.46% | -144.92% |
| Gross Margin | 81.64% | 54.84% |
| Operating Margin | 13.51% | -159.94% |
| Revenue Growth (YoY) | +96.43% | +263.55% |
| FCF Yield | 1.54% | -8.54% |
| Debt / Equity | 93.86 | 7.96 |
| Current Ratio | 3.13 | 2.41 |
Which is better: Alnylam Pharmaceuticals, Inc. or Moderna, Inc.?
- ✓Larger by market cap: Alnylam Pharmaceuticals, Inc.
- ✓More profitable (net margin): Alnylam Pharmaceuticals, Inc.
- ✓Faster revenue growth: Moderna, Inc.
- ✓Higher free-cash-flow yield: Alnylam Pharmaceuticals, Inc.
Across 9 available metrics, Alnylam Pharmaceuticals, Inc. leads 5–4.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Alnylam Pharmaceuticals, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.